South Africa

Population 2018: 58 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceººº</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- 3.4% (2.5–4.3) for new cases
- 7.1% (4.8–9.5) for previously treated cases

TB case notifications, 2018

- Total new and relapse: 227,999
  - 71% tested with rapid diagnostics at time of diagnosis
  - 90% with known HIV status
  - 89% pulmonary
  - 70% bacteriologically confirmedººº
  - 7% children aged 0–14 years
  - 37% women
  - 56% men

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 76% (57–110)
- TB patients facing catastrophic total costs: 22% (14–30)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 22% (14–30)
- Patients with known HIV status who are HIV-positive: 120,862 (59%)
  - on antiretroviral therapy: 104,625 (87%)

Drug-resistant TB care, 2018

- 92% of bacteriologically confirmed TB cases tested for rifampicin resistanceººº
  - 92% for new cases
  - 94% for previously treated cases

Laboratory-confirmed cases: 13,199 MDR/RR-TB, 553 XDR-TB

Patients started on treatment: 9,558 MDR/RR-TB, 539 XDR-TB

MDR/RR-TB cases tested for resistance to second-line drugs: 7,469

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 77% 240,332
- Previously treated cases, excluding relapse, registered in 2017: 59% 6,508
- HIV-positive TB cases registered in 2017: 75% 134,672
- MDR/RR-TB cases started on second-line treatment in 2016: 54% 11,159
- XDR-TB cases started on second-line treatment in 2016: 58% 601

TB preventive treatment, 2018

- 65% of HIV-positive people (newly enrolled in care) on preventive treatment
- 59% (54–65) of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

- National TB budget (US$ millions): 240
  - Funding source: 87% domestic, 13% international, 0% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-11-17
Data: www.who.int/tb/data